Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.

2.50
Hdl Handle:
http://hdl.handle.net/10541/85170
Title:
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
Authors:
Barrett-Lee, P J; Dixon, J M; Farrell, Carole; Jones, A; Leonard, R; Murray, N; Palmieri, C; Plummer, C J; Stanley, A; Verrill, Mark W
Abstract:
Anthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.
Affiliation:
Breast Unit, Velindre Cancer Centre, Cardiff, UK. peter.barrett-lee@velindre-tr.wales.nhs.uk
Citation:
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. 2009, 20 (5):816-27 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
May-2009
URI:
http://hdl.handle.net/10541/85170
DOI:
10.1093/annonc/mdn728
PubMed ID:
19153118
Type:
Article
Language:
en
ISSN:
1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBarrett-Lee, P Jen
dc.contributor.authorDixon, J Men
dc.contributor.authorFarrell, Caroleen
dc.contributor.authorJones, Aen
dc.contributor.authorLeonard, Ren
dc.contributor.authorMurray, Nen
dc.contributor.authorPalmieri, Cen
dc.contributor.authorPlummer, C Jen
dc.contributor.authorStanley, Aen
dc.contributor.authorVerrill, Mark Wen
dc.date.accessioned2009-11-02T14:45:47Z-
dc.date.available2009-11-02T14:45:47Z-
dc.date.issued2009-05-
dc.identifier.citationExpert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. 2009, 20 (5):816-27 Ann. Oncol.en
dc.identifier.issn1569-8041-
dc.identifier.pmid19153118-
dc.identifier.doi10.1093/annonc/mdn728-
dc.identifier.urihttp://hdl.handle.net/10541/85170-
dc.description.abstractAnthracyclines are considered to be among the most active agents for the treatment of breast cancer. However, their use is limited by cumulative, dose-related cardiotoxicity. Such cardiotoxicity results in a permanent loss of cardiac myocytes and a progressive reduction in cardiac function following each subsequent dose of anthracycline. Initially, damage to the heart is subclinical; however, increasingly impaired cardiac function can result in cardiovascular symptoms, with serious cardiac injury resulting in chronic heart failure. Since the early detection and treatment of cardiotoxicity can reduce its clinical effects, it is important that oncologists are aware of these adverse effects and manage them appropriately. This review examines the risk factors for anthracycline-associated cardiotoxicity and offers recommendations on strategies to reduce the cardiotoxicity of anthracyclines in the management of patients with advanced breast cancer.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAnthracyclines-
dc.subject.meshAntibiotics, Antineoplastic-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDrug Monitoring-
dc.subject.meshFemale-
dc.subject.meshHeart Diseases-
dc.subject.meshHumans-
dc.subject.meshPatient Selection-
dc.subject.meshPractice Guidelines as Topic-
dc.subject.meshRisk Assessment-
dc.subject.meshRisk Factors-
dc.titleExpert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.en
dc.typeArticleen
dc.contributor.departmentBreast Unit, Velindre Cancer Centre, Cardiff, UK. peter.barrett-lee@velindre-tr.wales.nhs.uken
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.